Geron Corp. (GERN, Trade ) shares fell 51%. The biotech firm said Monday that it's discontinuing its Phase II study of imetelstat in metastatic HER2-negative breast cancer because median progression-free survival was shorter than the comparison treatment. I'm working tell I'm 70 or till I drop dead. Cry me a river.
DISASTER, DISASTER, DISASTER, DISASTER.
GOOD LUCK IN THIS RIGGED CASINO,
No comments:
Post a Comment